These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25989713)

  • 41. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
    Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
    Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results?
    Szmurło D; Schubert A; Kostrzewska K; Ryś P; Skrzekowska-Baran I
    Pol Arch Med Wewn; 2011 Oct; 121(10):345-50. PubMed ID: 22045095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
    J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the future.
    Tucker DM; Palmer AJ
    Prim Care Diabetes; 2011 Apr; 5(1):9-17. PubMed ID: 21071296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
    Men P; Qu S; Luo W; Li C; Zhai S
    Diabetes Obes Metab; 2020 Jan; 22(1):107-115. PubMed ID: 31469217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
    Wake N; Hisashige A; Katayama T; Kishikawa H; Ohkubo Y; Sakai M; Araki E; Shichiri M
    Diabetes Res Clin Pract; 2000 Jun; 48(3):201-10. PubMed ID: 10802159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
    Cummins E; Royle P; Snaith A; Greene A; Robertson L; McIntyre L; Waugh N
    Health Technol Assess; 2010 Feb; 14(11):iii-iv, xi-xvi, 1-181. PubMed ID: 20223123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF; Curtis BH; Valentine WJ
    J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Anyanwagu U; Mamza J; Donnelly R; Idris I
    Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.
    Pollock RF; Chubb B; Valentine WJ; Heller S
    Diabetes Metab Syndr Obes; 2018; 11():217-226. PubMed ID: 29844693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK.
    Bain SC; Bekker Hansen B; Hunt B; Chubb B; Valentine WJ
    J Med Econ; 2020 Jan; 23(1):98-105. PubMed ID: 31311364
    [No Abstract]   [Full Text] [Related]  

  • 60. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
    Laxy M; Wilson ECF; Boothby CE; Griffin SJ
    Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.